- Brand names:
- Pharmaceutical Company:
- Condition/Indication: X-linked hypophosphataemia
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 1.3MB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 417KB)
Burosumab – March 2022
Burosumab: Injection 10 mg in 1 mL, Injection 20 mg in 1 mL, Injection 30 mg in 1 mL; Crysvita®
Last updated
1 July 2022